Commercialization Plan

GCC Cancer VaccineGCC CAR-T
  • Viral Gene has completed the phase I clinical trial and is in the process of applying for an FDA approval to conduct a phase II clinical trial

  • Expected to be designated as an orphan drug and breakthrough therapy
    • Early entry into the market is anticipated upon completion of the phase II clinical trial

  • Viral Gene possesses the right to commercialize the GCC Cancer Vaccine worldwide

  • Phase IIa clinical trial expected to begin in 2019 with planned completion in 2021
    • During this stage, Viral Gene is planning to execute license agreements with global pharmaceutical companies for commercialization and sales
    • Expect to generate earnings after 2021 through these agreements

  • Phase IIb clinical trial completion expected by 2023 with anticipated market release in 2024-2025
    • Expect to generate continuous earnings from running royalties through sales beginning in 2024-2025
  • Liminatus has completed the preclinical trial stage and is in the process of applying for an FDA approval to conduct phase I clinical trial

  • Expected to be designated as an orphan drug and breakthrough therapy
    • Early entry into the market is anticipated upon completion of the phase II clinical trial

  • Liminatus possesses the right to commercialize the GCC CAR-T worldwide

  • Phase I clinical trial expected to begin in 2020 with planned completion in 2022
    • During this stage, Liminatus is planning to execute license agreements with global pharmaceutical companies for commercialization and sales
    • Expect to generate earnings after 2022 through these agreements

  • Phase II clinical trial completion expected by 2025 with anticipated market release in 2026
    • Expect to generate continuous earnings from running royalties through sales beginning in 2026